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ORIGINAL ARTICLE
Genomic proﬁling of thousands of candidate polymorphisms
predicts risk of relapse in 778 Danish and German childhood
acute lymphoblastic leukemia patients
A Wesołowska-Andersen1,11, L Borst2,11, MD Dalgaard1, R Yadav1, KK Rasmussen2, PS Wehner3, M Rasmussen4, TF Ørntoft5,
I Nordentoft5, R Koehler6, CR Bartram6, M Schrappe7, T Sicheritz-Ponten1, L Gautier1, H Marquart8, HO Madsen8, S Brunak1, M Stanulla9,
R Gupta1,12 and K Schmiegelow2,10,12
Childhood acute lymphoblastic leukemia survival approaches 90%. New strategies are needed to identify the 10–15% who evade
cure. We applied targeted, sequencing-based genotyping of 25 000 to 34 000 preselected potentially clinically relevant single-
nucleotide polymorphisms (SNPs) to identify host genome proﬁles associated with relapse risk in 352 patients from the Nordic
ALL92/2000 protocols and 426 patients from the German Berlin–Frankfurt–Munster (BFM) ALL2000 protocol. Patients were enrolled
between 1992 and 2008 (median follow-up: 7.6 years). Eleven cross-validated SNPs were signiﬁcantly associated with risk of relapse
across protocols. SNP and biologic pathway level analyses associated relapse risk with leukemia aggressiveness, glucocorticosteroid
pharmacology/response and drug transport/metabolism pathways. Classiﬁcation and regression tree analysis identiﬁed three
distinct risk groups deﬁned by end of induction residual leukemia, white blood cell count and variants in myeloperoxidase (MPO),
estrogen receptor 1 (ESR1), lamin B1 (LMNB1) and matrix metalloproteinase-7 (MMP7) genes, ATP-binding cassette transporters and
glucocorticosteroid transcription regulation pathways. Relapse rates ranged from 4% (95% conﬁdence interval (CI): 1.6–6.3%) for
the best group (72% of patients) to 76% (95% CI: 41–90%) for the worst group (5% of patients, Po0.001). Validation of these
ﬁndings and similar approaches to identify SNPs associated with toxicities may allow future individualized relapse and toxicity risk-
based treatments adaptation.
Leukemia (2015) 29, 297–303; doi:10.1038/leu.2014.205
INTRODUCTION
Host genome variants affect the complex biology involved in
pharmacokinetics/pharmacodynamics and need to be addressed
to identify the critical factors determining treatment outcomes.
Childhood acute lymphoblastic leukemia (ALL) has for several
reasons been a model disease for such research owing to its
frequency, well-described epidemiology, clinical characteristics
and biologic proﬁles within cytogenetically deﬁned subsets. In
general, childhood ALL is very chemosensitive, and patients are
almost uniformly treated within collaborative groups that stratify
treatment according to known molecular aberrations in the
leukemic clone, clinical characteristics and treatment response.1,2
Most contemporary treatment protocols achieve 5-year event-free
survival rates above 80%.3 However, even with risk group-adapted
treatment there is a wide diversity in cure rates, partly explainable
by both host and cancer genomes.3,4 Several candidate gene
studies have associated inherited polymorphisms with treatment
response and cure rates in childhood ALL.1,2,5–7 Still, the biologic
relevance and interpretation of multiple single-nucleotide poly-
morphisms (SNPs) identiﬁed in recent genome-wide association
studies (GWAS) remain unclear, as the functions of several of the
most signiﬁcant genes are unknown,8 and effect sizes of single
SNP associations are in any case extremely limited. To address
some of these limitations and complement the GWAS approach,
we applied a multiplexed targeted sequencing method allowing
screening of 25 000–34 000 preselected SNPs within biologic
domains potentially relevant to childhood ALL, allowing both
single variants and multiple SNPs acting in the same pathways to
be explored for association with relapse, and ﬁnally combining it
with known clinical risk factors in a predictive proﬁle.9
MATERIALS AND METHODS
Danish patients were 1–15 years of age and diagnosed 1992–2008 with
B-cell precursor ALL (BCP-ALL) or T-lineage ALL and treated according to
the Nordic Society for Pediatric Hematology and Oncology (NOPHO) ALL92
(N= 227) or NOPHO ALL2000 protocols (N=268) (Figure 1, Supplementary
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Online Material and Supplementary Tables 1). These two treatment
protocols are very similar and included a 4-week, 3-drug induction phase
(prednisolone, vincristine and doxorubicin (with intrathecal methotrexate))
with no glucocorticosteroid prephase, a risk group-adapted consolidation
phase and methotrexate/6-mercaptopurine maintenance therapy up until
2 to 2.5 years from diagnosis10 (detailed in Supplementary Online Material).
End of induction minimal residual disease (MRD) measurements were
available for 73% of NOPHO ALL2000 patients, but not included in risk
stratiﬁcation.10 For cross-protocol validation of relapse-predictive host
genomic variants, 500 German childhood ALL patients 1–18 years at
diagnosis were included, all treated according to the BFM ALL2000
protocol. The BFM ALL2000 protocol included a 1-week prednisolone
prephase, a 4-week, 4-drug induction phase (prednisolone or dexametha-
sone, vincristine, doxorubicin and L-asparaginase (with intrathecal metho-
trexate)), a risk group-adapted consolidation phase and methotrexate/
6-mercaptopurine maintenance therapy until 2 years from diagnosis1,11,12
(Supplementary Online Material). A total of 352 Danish and 426 German
patients were eligible for the ﬁnal relapse-risk analysis (Figure 1 and
Supplementary Tables S1). Patients were enrolled between 1992 and 2008
with a median follow-up of 7.6 years (50% range: 5.3–9.2 years) for patients
in ﬁrst remission. In this study, both bone marrow and extramedullary
relapses were events of interest. Owing to the complexity of the
bioinformatic analysis and the application of nonlinear machine learning,
and as it is uncertain how to weight competing events (induction failures,
deaths in remission and second cancers), we chose, in this exploratory,
hypothesis-generating study, to exclude patients with such events already
at the time of diagnosis of ALL (Figure 1). The study was conducted in
accordance with the Declaration of Helsinki Principles of 1975, and
approved by the Danish Data Protection Agency, the Committee on
Biomedical Research Ethics and by the Ethics Committee of the Hannover
Medical School, Hannover, Germany.
SNP selection and bait design have been previously described in detail
(Wesolowska et al.9 and Supplementary Online Material). SNPs were
selected to cover all known and putative clinically relevant genetic
variation with regard to childhood ALL treatment (13 drugs), drug
pharmacokinetics and pharmacodynamics, relapse risk and several
toxicities (Supplementary Figure S1). In short, clinically important genes
and SNPs for the 13 most commonly administered antileukemic drugs
were evaluated with regard to genes encoding proteins involved in
metabolism, transport, target proteins, regulation of drug-target response
and to some extent drug-related toxicity (e.g. coagulation, immune
function) (Supplementary Online Material). Initially, this was carried out by
literature curation, and then expanded to cover additional aspects of
response to chemotherapy such as genes encoding proteins involved in
apoptosis pathways and DNA repair. This also included consultations with
experts within such areas and through various online resources
(Supplementary Online Material). Finally, known drug–protein associations
and ﬁrst-order protein–protein interactions were evaluated and added
(Supplementary Online Material and Supplementary Figure S1).9 Approxi-
mately half of the selected genomic variants were in noncoding regions.
The selected genes were then screened for known polymorphisms with
putative functional consequence on their transcript (Supplementary Table
S3). Baits for the SureSelect Target Enrichment System (protocol version 1.2
April 2009; Agilent Technologies, Santa Clara, CA, USA) were designed for
all identiﬁed SNPs. The ﬁrst design included baits targeting 25 086 clinically
relevant SNPs in 1540 genes (Supplementary Figure S2). As baits covered
more genomic material than just the targeted SNPs, readouts on the
targeted regions covered 116 646 known human variants (Supplementary
Table S4). This panel was subsequently updated after sequencing the ﬁrst
group of patients (from NOPHO ALL2000) (Supplementary Online Material
and Supplementary Tables S3 and S4). Thus, the NOPHO ALL92 and BFM
ALL2000 cohorts were screened using an expanded bait design, covering
33 683 SNPs in 2254 genes. The genomic targets of the two panels are
shown in Supplementary Figure S2.
The patients were genotyped for either of the two SNP panels by
multiplex targeted sequencing as described previously.9 Brieﬂy, the Agilent
SureSelect Target Enrichment System protocol (protocol version 1.2 April
2009; Agilent Technologies) was modiﬁed, allowing nucleotide barcoding,
and then pooling of samples before target enrichment and sequencing.
Genomic DNA from leukemia remission samples was sheared, puriﬁed,
end-repaired and 3′ adenylated. Custom-made adaptors containing unique
four-base barcodes were ligated to the DNA fragments before size
selection and ampliﬁcation. The DNA libraries were subsequently mixed in
groups of up to eight samples, and the pooled libraries were hybridized to
the custom-designed baits. Posthybridization ampliﬁcation PCR was
performed, and the pooled libraries were sequenced (Supplementary
Online Material). The sequencing reads were mapped to the reference
human genome (GRCh37), and SNP calling was performed (Supplementary
Figure S3). The threshold set for SNP calling was minimum 10×
sequencing depth. Data quality control and the individual–SNP association
Figure 1. Patient ﬂow. Overview of the patients included in the study. CEU, Utah residents with ancestry from northern and western Europe.
*BFM patients were selected upon availability of germline DNA and consecutively enrolled up to the predeﬁned number of 500.
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analyses were performed in PLINK (version 1.07).13 Patient samples not
clustering together with the HapMap central European ancestry samples in
the principal component analysis (Supplementary Figures S4 and S5) were
removed.14 To make sure that the data did not contain any bias arising
either from sequencing or data processing, the observed minor allele
frequencies (MAFs) of the genotyped SNPs were plotted against the
HapMap CEU-reported MAFs for the 5962 SNPs, where data were available
(Supplementary Figure S7). Furthermore, SNPs for which o50% of the
patients could be genotyped at the minimum depth of 10× and SNPs with
MAF o1% were excluded from the analyses. To validate readouts,
genotyping from this experiment was compared with genotype calls
obtained from the Illumina Human 1M-Duo SNP chip performed on a
subset of patients (N= 275, overlap of 2394 SNPs on both platforms). The
mean genotyping concordance of those two methods was 98.2%
(Supplementary Online Material).
SNP associations
Single SNPs were explored for associations with risk of relapse using a
Fisher’s exact test separately for the NOPHO and BFM cohorts. P-values
obtained were corrected for multiple testing by adaptive permutation, and
subsequently only SNPs with adjusted P-values below 0.05 in both cohorts
were considered signiﬁcant.15 Besides investigating such contribution of
individual variations, the combined effects of multiple SNPs acting in the
same biologic pathways were investigated using nonlinear machine
learning. All pathways from the Reactome database16 and 12-drug
metabolism pathways from the PharmGKB database (ref. 27 in
Supplementary Online Material), with up to 193 SNPs in a pathway, were
interrogated. Brieﬂy, ANN models including all combinations of up to three
SNPs together with white blood cell counts (WBC) and age at diagnosis
were tested within each pathway and stepwise expanded with up to 15
SNPs in a pathway, if threefold cross-validated performance improved
(Supplementary Online Material) (Figure 2). The best model for each
pathway was then chosen, and the most informative pathway models were
combined with clinical information in classiﬁcation and regression tree
(CART) analysis assigning for each pathway a score from 1 to 10 for every
patient based on the relapse prediction from the neural network. As
induction therapy differed between the Danish and German cohorts, each
of these was dichotomously subdivided based on the approximate median
end of induction MRD levels in each cohort being 10− 3 and 10− 4 in
NOPHO and BFM cohorts, respectively (Supplementary Online Material).
RESULTS
Of the genotyped patients (N= 869), 808 fulﬁlled the quality
control and the European ancestry criteria (Figure 1), of which 778
patients could be included in the ﬁnal relapse-risk analysis. The
majority of genotyped variants had very low heterogeneity (MAF
o1%) between patients and thus did not contribute with
sufﬁcient power to the single SNP analysis. Thus, a total of 4260
and 3865 SNPs in the NOPHO and the BFM cohorts were included
in the relapse-risk analysis, respectively.
The QQ plots showed good agreement with the null distribu-
tion and absence of genomic inﬂation (Supplementary Figure S8),
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Figure 2. Flow diagram of the ANN models and CART (see also Supplementary Online Material). For pathway analysis, we included all
nonsynonymous coding, frameshift coding, stop codon and splice site SNPs genotyped in this study with MAF above 0.005 residing in the
pathway genes for pathways in Reactome database and for the 12-drug metabolism pathways from the PharmGKB database. Each pathway
had between 1 and 193 SNPs, and each SNP was encoded by three values between 0 and 1 corresponding to likelihood of each genotype
calculated from VCF ﬁle produced by SAMtools (see Supplementary Online Material). Associations with relapse risk were performed by
training feedforward ANNs with backpropagation on subsets of SNPs from each pathway with threefold cross-validation. For each pathway, all
combinations of up to three SNPs were assessed by means of MCC. The combinations were then further iteratively increased up to 15 SNPs by
adding another SNP to the top 20 previous combinations of SNPs, if the MCC increased by at least 0.01. Pathways were then ranked by MCC of
the best combination of SNPs for each pathway, and the most predictive pathways for relapse were then included in the CART analysis. This
included the 426 patients with complete information on sex, age and WBC at diagnosis, immunophenotype, karyotype, end of induction MRD
and risk group. For the large group of patients with low MRD, the SNP proﬁles of the top Reactome/PharmGKB pathways were included to
explore their relapse prediction for this patient subset.
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and several loci were signiﬁcantly associated with risk of relapse
(Supplementary Figure S9). A total of 188 and 152 SNPs were
associated with relapse risk in the NOPHO and BFM cohorts,
respectively (Supplementary Tables S5 and S6). As some of these
will reﬂect chance ﬁndings, we included in the subsequent
analyses only the 11 SNPs that were associated with relapse
risk in both cohorts. Importantly, these 11 SNPs were related
to risk of relapse independent of other known risk factors
(Table 1, Supplementary Table S7 and Supplementary Online
Material). As further support of their biologic signiﬁcance,
Kaplan–Meier analyses for these SNPs showed a general tendency
of gene dose effects (0 versus 1 versus 2 alleles associated
with increased risk of relapse) with log-rank trend P-values
ranging from 4.8×10−6 for rs3216144 (matrix metalloproteinase 7,
MMP7) to 0.03 for rs35721373 (dysferlin, DYSF), respectively
(Supplementary Figure S9).
Next, functional SNPs were grouped by biologic pathways, and
the relevance of the pathways to risk of relapse was assessed by
training ANNs on different combinations of SNPs from each
pathway, allowing nonlinear correlations between SNPs. The top-
associated Reactome pathway16 ranked by Matthew’s correlation
coefﬁcient17 (MCC, ranging from 0 to 1) was ‘ATP-binding cassette
(ABC) family protein-mediated transport’ (MCC= 0.33, area under
the receiver-operator curve (AUC) = 0.69) (Supplementary Table S8).
Similarly, 12-drug metabolism pathways from the PharmGKB
database relevant for the administered drugs were investigated,18
and the top pathways were ‘Vinka Alkaloid Pathway, Pharmaco-
kinetics’ (MCC= 0.321, AUC= 0.72), ‘Glucocorticoid Pathway
(Peripheral Tissue), Pharmacodynamics’ (MCC= 0.320, AUC= 0.75)
and ‘Methotrexate Pathway (Brain Cell), Pharmacokinetics’
(MCC= 0.320, AUC= 0.70) (Supplementary Table S9).
To explore and illustrate the combined signiﬁcance of clinical
data and host genomic ﬁndings, CART analysis was applied to
subclassify sequentially patients in a multivariate model, including
the 426 patients from both cohorts with complete information on
sex, age, immunophenotype, WBC, leukemia karyotype, end of
induction MRD, risk group and genotypes of the 11 cross-cohort-
associated SNPs (Figure 3a). A total of 426 patients were included.
End of induction MRD levels divided the patients into two major
groups: one group with high MRD levels (i.e. above median for
that cohort) and a high risk of relapse, which could be further
stratiﬁed by SNPs in the myeloperoxidase (MPO), estrogen
receptor 1 (ESR1), lamin B1 (LMNB1) and MMP7 genes, and
another large group with low MRD levels and low cumulative
relapse risk. As the latter group, because of its size, accounts for
25% of all relapses, a subsequent CART analysis with pathway
proﬁles for the top 10 Reactome and the PharmGKB pathways was
added (all having AUCs of approximately 0.70), which indicated a
role of ABC transporters and glucocorticosteroid transcription
regulation pathways (Figure 3b). Finally, based on MRD, WBC, the
aforementioned host genomic data and the resulting observed
incidence of relapse (Figures 3a and b), we could deﬁne three
large subsets of patients with signiﬁcant differences in the risk of
relapse (Po0.001). With 92% of projected relapses by Kaplan–
Meier analysis having been observed in the total cohort, the two
extreme subgroups of patients had 6-year cumulative risks of
relapse of 4% (95% conﬁdence interval: 1.6–6.3%) for the best
outcome group (71.5% of all patients) and 76% (95% conﬁdence
interval: 41–90%) for the worst outcome group (5% of all patients)
(Figure 3c and Table 2), leaving age, immunophenotype (BCP
versus T-ALL), cytogenetics (Table 2; high risk, that is, t(9;22),
hypodiploid, t(4;11); low risk, that is, high hyperdiploid, t(12;21);
other) and risk group nonsigniﬁcant with this approach. As MRD
was not available for all patients, an additional CART analysis was
performed not including MRD (Supplementary Figure S10). All four
SNPs from the original CART diagram remained signiﬁcant for
relapse prediction. Survival analysis taking into account the time
to event was also performed (Supplementary Figure S11), with
results largely agreeing with the model in Figure 3. Multivariate
regression analysis to predict risk of relapse found all the features
selected by CART analysis to be statistically signiﬁcant, with MRD
being the most signiﬁcant clinical factor (P= 7.9 × 10− 6), MPO
rs28730837 being the most signiﬁcant SNP region (P= 0.002) and
glucocorticosteroid pathway (transcription regulation, pharmaco-
dynamics) (P= 2.0 × 10− 13) being the most signiﬁcant pathway.
DISCUSSION
Today, many high-risk patients do not respond to intensiﬁed
treatment, but most relapses occur among non-high-risk patients.
The present study, using genomic candidate gene genotyping and
front-line bioinformatics analyses, provides a novel biology/
pharmacology-driven approach for outcome prediction and goes
beyond conventional genome-wide association studies (GWAS)
approaches, while still being more cost-effective than whole-
genome sequencing (for cost details see Supplementary Online
Material). The rapidly growing understanding of the complex
human genome and its derived functional biology allows selection
of candidate SNPs based on the current knowledge of pharma-
cogenomics, disease mechanisms, signaling pathways and protein
Table 1. SNPs associated with risk of relapse discovered in both Danish and German cohorts
SNP NOPHO ALL92 and 2000 BFM ALL2000 Combined cohorts
Rs ID Gene Cons P-value OR MAF relapse MAF CR P-value OR MAF relapse MAF CR MAF relapse MAF CR P-value OR
Rs3216144 MMP7 Regulatory 4.0E− 04 0.14 0.05 0.26 2.0E− 03 0.32 0.09 0.24 0.07 0.24 6.0E− 06 0.26
Rs10502001 MMP7 NSC 4.0E− 04 0.14 0.05 0.25 2.0E− 03 0.32 0.09 0.24 0.08 0.24 6.0E− 06 0.26
Rs10795242 AKR1C3 Intronic 8.6E− 03 2.13 0.31 0.17 3.7E− 02 1.85 0.24 0.15 0.27 0.16 5.0E− 04 2.01
Rs28730837 MPO NSC 4.7E− 02 4.26 0.06 0.02 1.5E− 02 3.19 0.06 0.02 0.06 0.02 1.0E− 03 3.60
Rs6139873 CHGB NSC 4.0E− 03 19.56 0.11 0.01 3.9E− 02 3.50 0.04 0.01 0.06 0.01 1.1E− 03 5.75
Rs1293945 ESR1 Regulatory 2.0E− 02 1.86 0.59 0.43 2.6E− 02 1.95 0.59 0.42 0.59 0.43 1.3E− 03 1.91
Rs3763156 LMNB1 Intronic 2.0E− 02 3.06 0.19 0.07 4.0E− 02 2.15 0.15 0.07 0.16 0.07 1.6E− 03 2.43
Rs55684978 HTR3D SC 1.6E− 02 8.08 0.07 0.01 3.2E− 02 3.85 0.04 0.01 0.05 0.01 1.8E− 03 4.88
Rs1058047 TMED7 Splice site 1.3E− 02 8.64 0.08 0.01 3.9E− 02 3.20 0.05 0.02 0.06 0.02 3.1E− 03 3.98
Rs35721373 DYSF SC 1.5E− 02 4.89 0.13 0.03 3.1E− 02 2.52 0.09 0.04 0.10 0.04 3.3E− 03 2.96
Rs6601899 AKR1C3 Intronic 3.9E− 02 1.77 0.31 0.20 3.6E− 02 1.80 0.24 0.15 0.27 0.17 3.3E− 03 1.84
Abbreviations: cons, consequence of the SNP on its transcript from Ensembl Variant Effect Predictor; MAF CR, minor allele frequency in complete remission
patients; MAF relapse, minor allele frequency in relapse patients; NSC, nonsynonymous coding; OR, odds ratio; P-value, adaptive permutation P-values;
SC, synonymous coding.
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interactions. Large-scale, genomic candidate gene setup facilitates
not only single SNP investigations but also associations of multiple
variations grouped by their putative function. Further associations
of combinations of SNPs grouped by biologic pathways tested
with neural network models enable detection of meaningful
nonlinear SNP interactions. The results obtained through these
strategies can provide conclusions at new levels of genomic
complexity, collectively emphasizing the importance of speciﬁc
biologic mechanisms for the phenotype.
The 11 cross-cohort relapse-associated SNPs resided in genes
previously suggested as markers for leukemia aggressiveness,
involved in steroid response, implicated in resistance mechanisms
or toxicities of certain drugs (Supplementary Online Material). The
pathway analysis strongly indicated an importance of the ABC
family protein-mediated transport, activation of matrix metallo-
proteinases, toll-like receptor cascade signaling and various signal-
transduction pathways, as well as involvement of the cell cycle.
The top-associated pathway ‘ABC family protein-mediated trans-
port’ conﬁrms the role of pharmacogenomics in drug response by
pointing to the importance of drug transport. The ATP-dependent
drug efﬂux pumps have broad substrate speciﬁcities; they
inﬂuence drug accumulation and are associated with the
development of resistance to anticancer drugs.19 Matrix metallo-
proteinases are involved in tumor progression,20 whereas the toll-
like receptor cascades and nucleotide-binding oligomerization
domain-containing protein 1 and 2 signaling pathways support a
role for the innate immune system function for proper drug
response or ALL biology.21,22
It is noteworthy that the three top drug metabolism pathways
for relapse risk corresponded to pharmacodynamics of gluco-
corticosteroids and pharmacokinetics of vinka alkaloids and
methotrexate. This emphasizes the clinical signiﬁcance of
glucocorticosteroid therapy and cell cycle-arresting agents such
as vincristine and methotrexate, and also highlights the potential
profound consequence of adverse drug disposition on the effect
of these agents.
As risk factors linked to host genomics, leukemia biology,
treatment response markers and drug pharmacokinetics accumu-
late, CART analysis facilitates integration of the different layers of
molecular complexity with patients’ clinical characteristics to
identify groups of patients with distinct treatment outcomes, and
accordingly candidates for such treatment adaption. Thus,
combining patients’ genotypes with their clinical features is likely
to explain treatment outcome better than single SNPs.
Even though the binary recursive partitioning of the CART
methodology offers an approach to patient classiﬁcations that is
easier to perceive from a biologic point of view and to apply in the
clinical setting, CART does not necessarily outperform conven-
tional, stepwise, multivariate regression analyses. Interactions
between variables (and combinations hereof) may be missed,
and the downstream decision branching may be unstable if one
variable is removed. Although the CART analysis presented here
classiﬁed patients into highly different prognostic subsets, and
conventional regression analysis conﬁrmed the most signiﬁcant
clinical feature, SNP and pathway, larger independent data sets
will be needed to determine which of these two biostatistical
approaches is superior for relapse prediction.
In future trials, the small group of patients who have the highest
risk of relapse can be offered intensiﬁed treatments, or be
candidates for phase 2 trials, whereas treatment reduction to
avoid speciﬁc toxicities may be relevant for the large subset of
patients who have a projected risk of relapse of o5%. In this
context, the least relapse-predictive drug metabolism pathways
may point to which drug doses potentially could be safely
reduced in complex combination chemotherapy, and/or to which
patients a speciﬁc drug is important owing to the patient’s
genomic variants.
Although further veriﬁcation is needed to strengthen the
ﬁndings, the present approach has, when compared with other
large-scale studies, the clear advantage of speciﬁcally targeting
potential causative variants, which reduces the need to investigate
genomic patterns of linkage disequilibrium, or conducting
Figure 3. CART analysis of sequentially subclassiﬁed patients by clinical data including WBC, end of induction MRD and genotypes of cross-
cohort relapse-associated SNPs for the 426 patients from both cohorts for whom these data were available. The most discriminatory WBC
value (74.5 × 109/l) is selected by the CART algorithm. Black and white color in the pie charts represents the percentage of patients who
experienced a relapse (black) or stayed in complete remission (white). One group with above median (for that cohort) MRD levels and a high
risk of relapse could be further stratiﬁed by SNPs in the myeloperoxidase (MPO), estrogen receptor 1 (ESR1), lamin B1 (LMNB1) andMMP7 genes (a).
Another group with low MRD and low cumulative relapse risk could be further stratiﬁed by pathway proﬁles of ABC transporters and
glucocorticosteroid transcription regulation pathways (b). (c) Kaplan–Meier plots of relapse risk for three subsets of patients identiﬁed by the
CART analysis. The groups were deﬁned by the observed incidence of relapse within each node of the graph in panels a and b as marked with
[A], [B] or [C] for the best, intermediate and worst outcome group, respectively (Po0.001). Vertical lines depict patients with relapse or lack of
further follow-up. F, favorable; GC, glucocorticosteroids; PD, pharmacodynamics; U, unfavorable.
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follow-up ﬁne-mapping studies. Functional prioritization of the
potential SNPs to be genotyped eliminates the difﬁculties linked
to GWAS when mapping signiﬁcant variants to genes and
genotypes, and can be more directly combined in functional
analyses. As an example, only one of the 134 SNPs associated to
relapse risk in the recent childhood ALL GWAS study of Yang
et al.8 was also genotyped in the present study, as the remaining
SNPs resided in noncoding or functionally unannotated regions,
and it was not found signiﬁcant. Moreover, as the associated SNPs
in most cases were difﬁcult to map to the gene on which they
exert their effects, it is difﬁcult to evaluate the involved biologic
mechanisms.
The present study combines large-scale genetic investigations
of a GWAS approach with the targeted focus of a candidate gene
approach. Thus, the major strength of our approach is that a wide
panel of functional SNPs was selected with various prior
assumptions of their potential relevance for childhood ALL
treatment outcome. Owing to annotation to speciﬁc pathways,
the results obtained are easier to interpret, and eventually to
implement in the clinic based on existing knowledge of ALL
disease mechanisms and pharmacokinetics and pharmacody-
namics of administered drugs. Thus, the SNP/pathway-based
approach can also be applied for prediction of speciﬁc side effects
of antileukemic therapy. Host genome proﬁles may then indicate
drugs with little importance for cure but associated with a high
risk for side effects for speciﬁc patients, and this information could
be applied for tailored therapy. Accordingly, the strategies and
ﬁndings of this paper will be validated in the ongoing Nordic/
Baltic NOPHO ALL2008 protocol addressing risk grouping,23
occurrence of toxicities24 (including infections25) and risk of
relapse before they are included into future treatment allocation.
We acknowledge that not covering the whole genome will
certainly miss unknown, important genetic components of
treatment response, which may beneﬁt from alternative
genome-wide screening approaches such as GWAS or whole-
exome/transcriptome/genome sequencing, although the latter is
still burdened by high costs owing to required patient numbers
for statistical signiﬁcance, and requires extensive follow-up for
unannotated variants to be credibly accepted.
In conclusion, this large-scale integration of the knowledge of
disease mechanisms and drug pharmacokinetics/pharmaco-
dynamics in host genome studies in childhood ALL can offer
both signiﬁcant improvements to the current relapse prediction
algorithms, and, importantly, indicate speciﬁc directions for
leukemia response and toxicity risk-based treatments adaptation
for the individual patient.
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Table 2. Clinical characteristics of the patients in the three CART groups
Characteristics Group [A] patients Group [B] patients Group [C] patients
Total patients (%) 305 (71.5) 100 (23.5) 21 (5)
Gender
Male 174 (57) 63 (63) 12 (57)
Female 131 (43) 37 (37) 9 (43)
Age (years), mean (50% range) 5.32 (2.89–6.71) 7.38 (3.54–10.97) 7.09 (3.75–10.88)
WBC× 109/l, mean (50% range) 22.88 (4.6–26.5) 100.36 (7.5–108) 90.61 (4.51–121)
Immunophenotype
BCP-ALL 279 (91.5) 77 (77) 17 (81)
T-ALL 25 (8.2) 23 (23) 4 (19)
Other 1 (0.3) 0 (0) 0 (0)
MRD
Low 237 (77.7) 67 (67) 12 (57)
High 68 (22.3) 33 (33) 9 (43)
Cytogenetics
t(9;22) 4 (1.3) 1 (1) 1 (4.8)
t(1;19) 3 (1) 1 (1) 0 (0)
t(12;21) 79 (25.9) 13 (13) 2 (9.5)
t(4;11) 2 (0.65) 1 (1) 0 (0)
Hypodiploid 2 (0.65) 3 (3) 0 (0)
Hyperdiploid 81 (26.5) 16 (16) 1 (4.8)
Other 17 (5.6) 5 (5) 2 (9.5)
Normal/no data 120 (39.3) 61 (61) 15 (71.4)
Relapse distribution
Total 11 23 14
Bone marrow 8 (72.7) 19 (82.6) 12 (85.7)
CNS 1 (9.1) 3 (13.1) 4 (28.6)
Other 2 (18.2) 2 (8.7) 0 (0)
Abbreviations: ALL, acute lymphoblastic leukemia; BCP-ALL, B-cell precursor ALL; CART, classiﬁcation and regression tree; CNS, central nervous system
relapses (isolated and combined CNS relapses); MRD, minimal residual disease; T-ALL, T-lineage acute lymphoblastic leukemia; WBC, white blood
cell count.
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